1. Home
  2. EARN vs CKPT Comparison

EARN vs CKPT Comparison

Compare EARN & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • CKPT
  • Stock Information
  • Founded
  • EARN 2012
  • CKPT 2014
  • Country
  • EARN United States
  • CKPT United States
  • Employees
  • EARN N/A
  • CKPT N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • CKPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • CKPT Health Care
  • Exchange
  • EARN Nasdaq
  • CKPT Nasdaq
  • Market Cap
  • EARN 187.6M
  • CKPT 172.4M
  • IPO Year
  • EARN 2013
  • CKPT 2017
  • Fundamental
  • Price
  • EARN $6.52
  • CKPT $3.13
  • Analyst Decision
  • EARN Hold
  • CKPT Strong Buy
  • Analyst Count
  • EARN 1
  • CKPT 3
  • Target Price
  • EARN N/A
  • CKPT $12.00
  • AVG Volume (30 Days)
  • EARN 755.8K
  • CKPT 753.4K
  • Earning Date
  • EARN 03-05-2025
  • CKPT 03-21-2025
  • Dividend Yield
  • EARN 14.72%
  • CKPT N/A
  • EPS Growth
  • EARN 277.67
  • CKPT N/A
  • EPS
  • EARN 1.02
  • CKPT N/A
  • Revenue
  • EARN N/A
  • CKPT $47,000.00
  • Revenue This Year
  • EARN N/A
  • CKPT N/A
  • Revenue Next Year
  • EARN $89.08
  • CKPT $300,658.78
  • P/E Ratio
  • EARN $6.37
  • CKPT N/A
  • Revenue Growth
  • EARN N/A
  • CKPT N/A
  • 52 Week Low
  • EARN $5.88
  • CKPT $1.38
  • 52 Week High
  • EARN $7.26
  • CKPT $4.50
  • Technical
  • Relative Strength Index (RSI)
  • EARN 46.33
  • CKPT 46.36
  • Support Level
  • EARN $6.46
  • CKPT $3.10
  • Resistance Level
  • EARN $6.60
  • CKPT $3.43
  • Average True Range (ATR)
  • EARN 0.10
  • CKPT 0.26
  • MACD
  • EARN -0.00
  • CKPT 0.00
  • Stochastic Oscillator
  • EARN 38.10
  • CKPT 33.03

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Share on Social Networks: